From CRISPR therapeutics to mRNA platforms, the biotech sector is rewriting the rules of disease — and delivering outsized returns for informed investors.
"We are witnessing the industrialization of biology. Every disease is now, in principle, a software problem."— Dr. George Church, Harvard Medical School
Global biotech market cap
Active clinical trials in longevity
FDA approvals with breakthrough designation
The technology that delivered COVID vaccines in record time is now being weaponized against tumors, genetic disorders, and the cellular machinery of aging itself.
Base editing, prime editing, and epigenome editing are moving from lab curiosity to clinical reality — with valuations to match.
While genomics grabbed headlines, proteomics quietly became the most actionable layer of biology for drug discovery — and early investors are taking notice.
"The companies that will define the next decade aren't just building drugs — they're building biological operating systems. The investment thesis has fundamentally changed."